PolySciTech (
www.polyscitech.com)
provides a wide variety of PEG-PLGA and reactive conjugate precursors such as
Mal-PEG-PLGA for drug delivery uses. Recently similar polymers have been
utilized to generate inhalable nanoparticles conjugated to Solanum tuberosum
lectin for deliver basic fibroblast growth factor to the brain as a potential
treatment for Alzheimer’s disease. Read more: Zhang, Chi, Jie Chen, Chengcheng Feng, Xiayan
Shao, Qingfeng Liu, Qizhi Zhang, Zhiqing Pang, and Xinguo Jiang.
"Intranasal nanoparticles of basic fibroblast growth factor for brain
delivery to treat Alzheimer's disease." International journal of
pharmaceutics 461, no. 1 (2014): 192-202. http://www.sciencedirect.com/science/article/pii/S0378517313010430
“Abstract: Disabilities caused by
neurodegeneration have become one of the main causes of mortality in elderly
population, with drug distribution to the brain remaining one of the most
difficult challenges in the treatment of the central nervous system (CNS)
diseases due to the existence of blood–brain barrier. Lectins modified
polyethylene glycol-polylactide-polyglycolide (PEG-PLGA) nanoparticles could
enhance the drug delivery to the brain following intranasal administration. In
this study, basic fibroblast growth factor (bFGF) was entrapped in
nanoparticles conjugated with Solanum tuberosum lectin (STL), which selectively
binds to N-acetylglucosamine on the nasal epithelial membrane for its brain
delivery. The resulting nanoparticles had uniform particle size and negative
zeta potential. The brain distribution of the formulations following intranasal
administration was assessed using radioisotopic tracing method. The areas under
the concentration–time curve of 125I-bFGF in the olfactory bulb, cerebrum, and cerebellum
of rats following nasal application of STL modified nanoparticles (STL-bFGF-NP)
were 1.79–5.17 folds of that of rats with intravenous administration, and
0.61–2.21 and 0.19–1.07 folds higher compared with intranasal solution and
unmodified nanoparticles, respectively. Neuroprotective effect was evaluated
using Mirror water maze task in rats with intracerebroventricular injection of
β-amyloid25–35 and ibotenic acid. The spatial learning and memory of
Alzheimer's disease (AD) rats in STL-bFGF-NP group were significantly improved
compared with AD model group, and were also better than other preparations. The
results were consistent with the value of choline acetyltransferase activity of
rat hippocampus as well as the histological observations of rat hippocampal
region. The histopathology assays also confirmed the in vivo safety of
STL-bFGF-NP. These results clearly indicated that STL-NP was a promising drug
delivery system for peptide and protein drugs such as bFGF to enter the CNS and
play the therapeutic role. Keywords: Basic fibroblast growth factor (bFGF);
Solanum tuberosum lectin (STL); Brain delivery; Nanoparticles; Intranasal
administration; Alzheimer's disease (AD)”
No comments:
Post a Comment